Open AccessChemotherapy‐induced peripheral neurotoxicity: A critical analysis
Author(s) -
Park Susanna B.,
Goldstein David,
Krishnan Arun V.,
Lin Cindy SY,
Friedlander Michael L.,
Cassidy James,
Koltzenburg Martin,
Kiernan Matthew C.
Publication year - 2013
Publication title -
ca: a cancer journal for clinicians
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 62.937
H-Index - 168
eISSN - 1542-4863
pISSN - 0007-9235
DOI - 10.3322/caac.21204
Subject(s) - medicine , neurotoxicity , cancer , peripheral neuropathy , bortezomib , chemotherapy induced peripheral neuropathy , oncology , chemotherapy , breast cancer , vinca , colorectal cancer , thalidomide , intensive care medicine , toxicity , multiple myeloma , pharmacology , diabetes mellitus , endocrinology
With a 3‐fold increase in the number of cancer survivors noted since the 1970s, there are now over 28 million cancer survivors worldwide. Accordingly, there is a heightened awareness of long‐term toxicities and the impact on quality of life following treatment in cancer survivors. This review will address the increasing importance and challenge of chemotherapy‐induced neurotoxicity, with a focus on neuropathy associated with the treatment of breast cancer, colorectal cancer, testicular cancer, and hematological cancers. An overview of the diagnosis, symptomatology, and pathophysiology of chemotherapy‐induced peripheral neuropathy will be provided, with a critical analysis of assessment strategies, neuroprotective approaches, and potential treatments. The review will concentrate on neuropathy associated with taxanes, platinum compounds, vinca alkaloids, thalidomide, and bortezomib, providing clinical information specific to these chemotherapies. CA Cancer J Clin 2013;63:419‐437. © 2013 American Cancer Society, Inc.